There were few surprises in Destiny Pharma’s interim results as the recent achievements on its two lead Phase 3-ready products had previously been announced. We have made minor changes to our forecasts but none to our valuation as a result of the interims. Destiny’s new CEO delivered a polished and knowledgeable presentation only twelve days into the job handling analysts’ questions with ease and delegating to Destiny’s CFO and CSO where appropriate. We have delved into the details of the analysts’ meeting in the body of this note (see PDF for full details).